Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 12, Number 5—May 2006

Historical Lassa Fever Reports and 30-year Clinical Update

Article Metrics
citations of this article
EID Journal Metrics on Scopus
Abe M. Macher*Comments to Author  and Martin S. Wolfe†‡§
Author affiliations: *US Public Health Service (retired), Bethesda, Maryland, USA; †Travelers Medical Service of Washington, Washington, DC, USA; ‡George Washington University School of Medicine, Washington, DC, USA; §Georgetown University School of Medicine, Washington, DC, USA

Cite This Article


Five cases of Lassa fever have been imported from West Africa to the United States since 1969. We report symptoms of the patient with the second imported case and the symptoms and long-term follow-up on the patient with the third case. Vertigo in this patient has persisted for 30 years.

Lassa fever is a viral hemorrhagic fever caused by a rodentborne arenavirus that is endemic in West Africa. In 2004, the Centers for Disease Control and Prevention (CDC) reported a fatal case of Lassa fever in New Jersey (1). CDC noted that ≈20 imported cases of Lassa fever had been seen outside West Africa. Five patients with imported disease have been hospitalized in the United States (Table). We report the signs and symptoms of the second patient in this group of 5 patients and the signs and symptoms and long-term follow-up of the third patient, both aid workers who became ill in 1975 while serving in Sierra Leone. Their clinical courses were complicated by severe neurologic dysfunction, including unilateral sensorineural deafness and vertigo.

Case 1

In February 1975, a 26-year-old American aid worker in Sierra Leone was hospitalized with severe abdominal pain. No cause was determined, and she was discharged. In March 1975, watery diarrhea, fever, chills, headache, myalgias, arthralgias, and conjunctival injection developed. She was hospitalized, and physical examination showed posterior cervical, axillary, and inguinal lymphadenopathy. She was empirically treated for malaria and amebiasis.

Nevertheless, fever persisted, she lost 2.7 kg, and pleuritic chest pain developed. In April 1975, she was air evacuated and admitted to a hospital in Washington, DC. Although she was afebrile, generalized lymphadenopathy was still present, and a chest radiograph showed left-sided pleural effusion. Thoracentesis fluid was remarkable for eosinophilia, and examinations of blood showed 3%–35% peripheral eosinophilia. Knott's preparation of blood showed 3 sheathed microfilariae with nuclei extending into the tail, presumed to be Loa loa. A cervical lymph node biopsy showed follicular hyperplasia.

She was convalescing in the hospital when suddenly, while speaking on the telephone, she lost hearing unilaterally. An audiogram demonstrated unilateral sensorineural deafness. A serum specimen collected in May 1975 was sent to CDC, where an indirect fluorescent antibody (IFA) titer of 256 was demonstrated against Lassa fever virus (P. Rollin, pers. comm.). She was discharged with residual unilateral deafness.

Case 2

In December 1975, abdominal cramps, nausea, vomiting, diarrhea, fatigue, headaches, retroorbital pain, aching shoulders, and severe low back pain developed in a 43-year-old American aid worker in Sierra Leone.1 Her aching progressed to total body pain, which she described as "severe pain in her bones, as if they were breaking" (from patient's medical chart). Her symptoms persisted, and in February 1976, nocturnal fevers and sweats developed. She experienced dizziness and syncope and was hospitalized. She was hypotensive with blood pressure as low as 70/40 mm Hg (compared to 120/80 mm Hg in June 1975) and had insomnia. She was empirically treated for malaria and discharged. Her symptoms reappeared, accompanied by persistent vomiting, shooting pain in the right ear, neck pain, paresthesias, and alopecia. She lost 4 kg. In March 1976, she was air evacuated and admitted to a hospital in Washington, DC.

During her hospitalization in Washington, she was afebrile. However, fatigue, headache, neck pain, nausea, low back pain, and insomnia persisted. She had costochondral and diffuse abdominal tenderness and ecchymoses at intramuscular injection sites (antiemetics). She was unable to read for more than a few minutes, as her eyes would tire and begin to hurt. She experienced dysmorphopsias, difficulty with hearing, severe depression, and numerous episodes of lightheadedness, unsteadiness, dizziness, and vertigo. Vertigo occurred in both supine and standing positions up to 5 times per day. Although she was hypotensive, she was not orthostatic. Neurologic examination found left-sided facial weakness, right-sided Babinski reflex, and the Weber test lateralized to the left. Audiometry and positional and caloric nystagmography results were unremarkable.

A serum specimen obtained on March 1 showed an IFA titer of 64 against Lassa virus. Lassa virus was recovered from a March 3 urine specimen. On March 10, a serum specimen demonstrated a complement fixation antibody titer of 16, a 4-fold rise compared to a titer <4 in a February 25 specimen drawn in Sierra Leone.

Although her vertigo persisted, she became normotensive (120/80 mm Hg) on March 28, 1976, and was discharged. However, during the next 30 years, she continued to experience fatigue, generalized weakness, headache, insomnia, depression, dysmorphopsias, paresthesias, lightheadedness, dizziness and syncope, and labile hypotension. She describes "fatigue so severe that I have no energy for days," "staggering when getting up," "inability to produce words at times," and "spells of loss of consciousness" (up to 15 minutes in duration, as noted by her husband). In 1992, a magnetic resonance imaging scan of the brain demonstrated periventricular hyperintense signals. As of February 2006, her symptoms persist.


Auditory or vestibular dysfunction may develop in patients with Lassa fever, and tinnitus, autophony, hearing loss, dizziness, vertigo, nystagmus, and ataxia have been reported (3,4). In their review of a 1989 nosocomial Lassa fever outbreak in a Nigerian hospital, Fisher-Hoch et al. (3) noted a high fever in the index patient, who was taken to surgery on February 25. The patient bled profusely and died later that night. The surgical nurse and a student nurse who washed blood-soaked cloths both became ill with febrile illnesses on March 7. Both became serologically positive for Lassa fever virus. The surgical nurse was traced to her village, where she was found to be almost totally deaf and severely ataxic.

Onset of deafness among patients with Lassa fever is a feature of the convalescent phase rather than the acute phase of the illness (4). Deafness was first reported as a complication of Lassa fever by White (5) and Henderson (6) in 1972. White noted that during a 1970 nosocomial hospital outbreak in Jos, Nigeria, deafness occurred in 4 of 23 hospitalized patients; a fifth patient reported intermittent tinnitus, and 3 patients experienced dizziness.

Among the now 24 reported patients with imported Lassa fever worldwide (1969–2004, Table A1, our 26-year-old aid worker is the only patient whose clinical course has been complicated by sensorineural deafness. Our second patient's clinical course has been remarkable for an array of acute and chronic neurologic and neuropsychiatric complications, including left-sided facial weakness, right-sided Babinski reflex, headache, paresthesias, vertigo, syncope, dysmorphopsias, fatigue, insomnia, and depression. Rose (7,8) reported a 1955–1956 outbreak of encephalomyelitis in Sierra Leone, which may represent the earliest recorded clinical description of Lassa fever; remarkably, vertigo developed in 30 of his 45 patients. Solbrig and McCormick (9) reported that neuropsychiatric sequelae of Lassa fever have included sleep disorders (e.g., insomnia), asthenia, multiple somatic complaints, psychosis, hallucinations, personality disorders, severe adjustment reactions, dementia, mania, and depression. Finally, our patient's ongoing labile hypotension may represent Lassa fever–induced damage to the brain stem with resultant autonomic dysfunction. Since our patient's array of persistent neurologic and neuropsychiatric symptoms have not changed, improved, or progressed since her episode of Lassa fever, we believe that they all may represent sequelae of Lassa fever–induced damage to the brain.

Dr Macher is a 30-year veteran of the US Public Health Service. He retired in the summer of 2005 and currently advocates for indigent inmates' access to the standard of care. His research interests include the effects of privatization on correctional health care and postrelease access to continuity of care.

Dr Wolfe is clinical professor of medicine at the George Washington Medical School and Georgetown Medical School, director of the private Parasitology Laboratory of Washington, Inc., and director of the Travelers Medical Service of Washington. His research interests include intestinal parasites and febrile diseases.



  1. Centers for Disease Control and Prevention. Imported Lassa fever—New Jersey, 2004. MMWR Morb Mortal Wkly Rep. 2004;53:8947.PubMedGoogle Scholar
  2. Zweighaft  RM, Fraser  DW, Hattwick  MA, Winkler  WG, Jordan  WC, Alter  M, Lassa fever: response to an imported case. N Engl J Med. 1977;297:8037. DOIPubMedGoogle Scholar
  3. Fisher-Hoch  SP, Tomori  O, Nasidi  A, Perez-Oronoz  GI, Fakile  Y, Hutwagner  L, Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. BMJ. 1995;311:8579. DOIPubMedGoogle Scholar
  4. Rybak  LP. Deafness associated with Lassa fever. JAMA. 1990;264:2119. DOIPubMedGoogle Scholar
  5. White  HA. Lassa fever: a study of 23 hospital cases. Trans R Soc Trop Med Hyg. 1972;66:390401. DOIPubMedGoogle Scholar
  6. Henderson  BE, Gary  GW, Kissling  RE, Frame  JD, Carey  DE. Lassa fever: virological and serological studies. Trans R Soc Trop Med Hyg. 1972;66:40916. DOIPubMedGoogle Scholar
  7. Rose  JR. A new clinical entity? Lancet. 1956;2:197.
  8. Rose  JR. An outbreak of encephalomyelitis in Sierra Leone. Lancet. 1957;273:9146. DOIPubMedGoogle Scholar
  9. Solbrig  MV, McCormick  JB. Lassa fever: central nervous system manifestations. J Trop Geogr Neurol. 1991;1:2330.
  10. Frame  JD, Baldwin  JM, Gocke  DJ, Troup  JM. Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings. Am J Trop Med Hyg. 1970;19:6706.PubMedGoogle Scholar
  11. Gilles  HM, Kent  JC. Lassa fever: retrospective diagnosis of two patients seen in Great Britain in 1971. BMJ. 1976;2:1173. DOIPubMedGoogle Scholar
  12. Woodruff  AW, Monath  TP, Mahmoud  AA, Pain  AK, Morris  CA. Lassa fever in Britain: An imported case. BMJ. 1973;3:6167. DOIPubMedGoogle Scholar
  13. Vella  EE. Lassa fever. Hospital Update. 1976;2:317.
  14. Zweighaft  RM, Fraser  DW, Hattwick  MA, Winkler  WG, Jordan  WC, Alter  M, Lassa fever: response to an imported case. N Engl J Med. 1977;297:8037. DOIPubMedGoogle Scholar
  15. Department of Health and Social Security. Annual report of the chief medical officer. On the state of the public health for the year 1976. London: The Department; 1977. p. 52–3.
  16. World Health Organization. Lassa fever surveillance. Wkly Epidemiol Rec. 1981;56:478.
  17. World Health Organization. Lassa fever surveillance. Wkly Epidemiol Rec. 1982;57:342.
  18. Cooper  CB, Gransden  WR, Webster  M, King  M, O'Mahony  M, Young  S, A case of Lassa fever: experience at St Thomas's Hospital. BMJ. 1982;285:10035. DOIPubMedGoogle Scholar
  19. Emond  RTD, Weir  WR, Bowen  ET, Llloyd  G, Southee  T. Managing Lassa fever. Lancet. 1984;2:926. DOIPubMedGoogle Scholar
  20. Fisher-Hoch  SP, Price  ME, Craven  RB, Price  FM, Forthall  DN, Sasso  DR, Safe intensive-care management of a severe case of Lassa fever with simple barrier nursing techniques. Lancet. 1985;2:12279. DOIPubMedGoogle Scholar
  21. Schlaeffer  F, Bar-Lavie  Y, Sikuler  E, Alkan  M, Keynan  A. Evidence against high contagiousness of Lassa fever. Trans R Soc Trop Med Hyg. 1988;82:311. DOIPubMedGoogle Scholar
  22. Hirabayashi  Y, Oka  S, Goto  H, Shimada  K, Kurata  T, Fisher-Hoch  SP, An imported case of Lassa fever with late appearance of polyserositis. J Infect Dis. 1988;158:8725. DOIPubMedGoogle Scholar
  23. Mahdy  MS, Chiang  W, McLaughlin  B, Derksen  K, Truxton  BH, Neg  K. Lassa fever: The first confirmed case imported into Canada. Can Dis Wkly Rep. 1989;15:1938.PubMedGoogle Scholar
  24. Holmes  GP, McCormick  JB, Trock  SC, Chase  RA, Lewis  SM, Mason  CA, Lassa fever in the United States. Investigation of a case and new guidelines for management. N Engl J Med. 1990;323:11203. DOIPubMedGoogle Scholar
  25. Schmitz  H, Kohler  B, Lane  T, Drosten  C, Veldkamp  PJ, Gunther  S, Monitoring of clinical and laboratory data in two cases of imported Lassa fever. Microbes Infect. 2002;4:4350. DOIPubMedGoogle Scholar
  26. Public Health Laboratory Service Communicable Disease Surveillance Center. Case of Lassa fever in a soldier returning to the United Kingdom. Commun Dis Rep CDR Wkly. 2003;13:12.
  27. Centers for Disease Control and Prevention. Imported Lassa fever—New Jersey, 2004. MMWR Morb Mortal Wkly Rep. 2004;53:8947.PubMedGoogle Scholar




Cite This Article

DOI: 10.3201/eid1205.050052

1Portions of this patient's clinical signs and symptoms were originally published in Zweighaft et al. (2).

Table of Contents – Volume 12, Number 5—May 2006

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.



Please use the form below to submit correspondence to the authors or contact them at the following address:

Abe Macher, PO Box 34032, Bethesda, MD 20827, USA; fax: 301-571-9578

Send To

10000 character(s) remaining.


Page created: January 12, 2012
Page updated: January 12, 2012
Page reviewed: January 12, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.